Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 247 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Male Clear all

Conditions: Insomnia
Interventions: 20 mg VEC-162, 50 mg VEC-162, 100 mg VEC-162, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more

Conditions: Healthy
Interventions: Ecopipam immediate release form, 90 mg controlled release form, 180 mg controlled release form; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: ABBV-1354; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Diabetic Nephropathy
Interventions: CTP-499; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Healthy, Renal Impairment
Interventions: quinine sulfate; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Healthy Volunteers
Interventions: HSV529, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers - Male and Female
Interventions: KP-001, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Kaken Pharmaceutical; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Sleep Deprivation
Interventions: SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: asimadoline; Drug
Lead sponsor: Tioga Pharmaceuticals; Industry
Eligibility: 18 Years to 56 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Renal Disease, End Stage
Interventions: Amisulpride IV, Amisulpride Oral Tablet; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Healthy Participants
Interventions: BMS-986365, Rabeprazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers, Healthy
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions: NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo; Dietary Supplement
Lead sponsor: Scott Silveira; Other
Eligibility: 60 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Beverly Hills, California

Conditions: Healthy
Interventions: BI 207127 NA; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Drug-drug Interaction
Interventions: HBI-3000, Paroxetine; Drug
Lead sponsor: HUYABIO International, LLC.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Healthy Male Participants
Interventions: BMS-986322; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers, Renal Impairment
Interventions: pudexacianinium chloride; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Anniston, Alabama • Tustin, California • Miami, Florida

Conditions: Urinary Tract Infections
Interventions: E. coli Nissle 1917; Drug
Lead sponsor: Elizabeth Lucas; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Acne
Interventions: Omnilux Clear Light Emitting Diode Treatment; Device
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Healthy
Interventions: [14C]Elpipodect; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Blood Loss, Healthy
Interventions: CM-1500; Device
Lead sponsor: Zynex Monitoring Solutions; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Male
Interventions: Aldafermin; Biological
Lead sponsor: NGM Biopharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: [14C]PF-05221304; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: varegacestat; Drug
Lead sponsor: Immunome, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Search by objective public record fields.

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

Safety, Tolerability, and Pharmacokinetics (PK) of CTP-499

Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment

Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection

A Study to Evaluate the Effects of KP-001 on the QT/QTc Intervals in Healthy Adults

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

A Metabolite Identification, Mass Balance, and PK Study of [14C]-Asimadoline to Healthy Adult Male Volunteers

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well

Open Label Trial of Nissle 1917

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

A Study of Elpipodect (MK-8189) Human Absorption, Metabolism, and Excretion in Healthy Male Participants (MK-8189-010)

Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw

Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects

Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects

A Phase 1 Mass Balance Study of Varegacestat